A new study led by researchers at the Icahn School of Medicine at Mount Sinai has found that adding the targeted therapy everolimus to standard carboplatin chemotherapy extends the time before disease ...

Long-Term Survival in High-Grade Serous Ovarian Cancer Compared With the General US Population: A 30-Year Landmark Analysis This study adds to the current literature because it is one of the largest ...

Neoadjuvant Chemotherapy With Oxaliplatin and Fluoropyrimidine Versus Upfront Surgery for Locally Advanced Colon Cancer: The Randomized, Phase III OPTICAL Trial Eligible adults had previously ...

Adding carboplatin to adjuvant chemotherapy with epirubicin plus cyclophosphamide followed by taxanes (EC-T) significantly improved outcomes in patients with early-stage triple-negative breast cancer ...

In patients with triple-negative breast cancer (TNBC), adding once‑weekly carboplatin to standard neoadjuvant taxane‑anthracycline chemotherapy was associated with a significant improvement in overall ...

A new study led by researchers at the Icahn School of Medicine at Mount Sinai has found that adding the targeted therapy everolimus to standard carboplatin chemotherapy extends the time before disease ...

Camrelizumab with carboplatin and nab-paclitaxel shows potential as a first-line treatment for ES-SCLC, with promising survival rates. The study identified biomarkers, including MUC17 alterations and ...

Please provide your email address to receive an email when new articles are posted on . Survival outcomes did not differ for patients with HNSCC who received radiotherapy with carboplatin-paclitaxel ...

Results from the phase 3 PAPILLON study show that first-line amivantamab plus carboplatin-pemetrexed (amivantamab-chemotherapy) was associated with numerically longer overall survival compared with ...